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The past few decades have been marked by numerous
admirable research eﬀorts and promising technological
advancements in the ﬁeld of research on protozoan parasites.
The parasites of this genre cause some devastating diseases
that pose alarming threat to the mankind. Though several
intervention strategies have been developed to get rid of
these parasites, they always seem to frustrate the eﬀorts
of the scientiﬁc community sooner or later. The interven-
tion strategies include identiﬁcation of novel drug targets,
development of target-based therapy, and development of
vaccines. that provide signiﬁcant impetus in the ﬁeld of
research pertaining to these parasites. In this context, several
reviews have appeared in the past few years elucidating
diﬀerent drug targets in these parasites. For example, Das
et al. [1], Bala˜ na-Fouce et al. [2], and others have described
the role of topoisomerases as potential drug targets in
these kinetoplastid protozoa. Urbina [3] has described the
lipid biosynthetic pathway as a possible chemotherapeutic
target whereas McConville [4] has elucidated the potential
of parasite surface glycoconjugates as possible drug targets.
Other targets include cysteine peptidases [5] and histone
deacetylases [6] of the trypanosomatid parasites.
Parasites of the genus Trypanosoma and Leishmania are
kinetoplastid protozoanparasitesthatcausetrypanosomiasis
and leishmaniasis, respectively. Parasites belonging to the
genus Plasmodium mainly cause malaria. These diseases are
prevalent in tropical and subtropical countries and cause
signiﬁcant morbidity and mortality. However, these diseases
are of the lowest priority because they oﬀer little or no
commercial incentives to the pharmaceutical companies.
This special issue is a much needed and timely com-
pilation of selected research and review articles in the
concerned ﬁeld. Though the selected papers are not a
comprehensive representation of the ﬁeld, but they represent
a rich mixture of multifaceted knowledge that we have the
pleasure of sharing with the readers. We would like to thank
all the authors for their excellent contributions and also the
reviewers for their eﬀorts in assisting us.
This special issue contains thirteen papers, of which ﬁve
are research papers, and the rest are review articles. The
ﬁve research articles mainly focus on development of new
drugs and targets and also shed light on novel therapeutic
intervention strategies. In the ﬁrst paper, S. Sengupta et al.
have established cryptolepine-induced cell death in the pro-
tozoanparasiteL.donovani.Interestingly,thedeathprocessis
augmented when the autophagic mechanism is inhibited by
speciﬁc chemical inhibitors, and this ﬁnding may form the
skeleton for novel therapeutic intervention strategies.
In the second paper, S. Teixeira de Macedo-Silva et al.
have investigated the eﬀect of the antiarrhythmic drug
amiodaroneonthepromastigotesandamastigotesformof L.
amazonensis. They have shown that this drug has antiprolif-
erative eﬀect on L. amazonensis promastigotes and amastig-
otes and causes depolarization of mitochondrial membrane
potential in both forms which ultimately leads to cell death
of the parasites. So this compound may serve as a potential
starting material for antileishmanial drug development.
In the third paper, L. Major and T. K. Smith. have
screened the MayBridge Rule of 3 Fragment Library to
identify compounds targeting Inositol-3-phosphate synthase2 Molecular Biology International
(INO1) which has previously been genetically validated as a
drug target against Trypanosoma brucei, the causative agent
of African sleeping sickness. By this approach, they have
identiﬁed 38 compounds that signiﬁcantly altered the Tm
of TbINO1. Four compounds showed trypanocidal activity
with ED50s in the tens of micromolar range, with 2 having a
selectivity index in excess of 250.
Topoisomerases are key enzymes that play a pivotal role
in various cellular processes and also serve as an important
drug target. In the paper, A. Roy et al. have described a syn-
thetic peptide, WRWYCRCK, with inhibitory eﬀect on the
essential enzyme topoisomerase I from the malaria-causing
parasite Plasmodium falciparum. Although Plasmodium fal-
ciparum does not belong to the order kinetoplastida, but
still it has several features common with the kinetoplastid
protozoanparasiteT. brucei,forexample,antigenicvariation.
The transition step from noncovalent to covalent DNA
binding of P. falciparum topoisomerase I is speciﬁcally
inhibited by this peptide while the ligation step of catalysis
remains unaﬀected. Molecular docking analyses further pro-
vide a mechanistic explanation for this inhibition. This work
provides evidence that synthetic peptides may represent a
new class of potential antiprotozoan drugs.
In the ﬁfth paper, J. Kaur et al. have performed bioinfor-
matic analysis of the Leishmania donovani long-chain fatty
acid Co-A ligase (LCFA) as a novel drug target. The authors
have previously found this enzyme to be diﬀerentially
expressed by Leishmania donovani amastigotes resistant to
antimonial treatment. In the present study, the authors
have conﬁrmed the presence of long-chain fatty acyl CoA
ligase gene in the genome of clinical isolates of Leishmania
donovani collected from the disease-endemic area in India
and propose that this enzyme serves as an important protein
and a potential target candidate for development of selective
inhibitors against leishmaniasis.
This special issue also features some timely and much
neededreviewarticlesintheﬁeld.Inthesixthpaper,S.Gupta
et al. have validated the role of a key enzyme, glucose-6-
phosphate dehydrogenase (G6PDH) in trypanosomatids as
an important drug target and discussed the possibility of
drug discovery targeting this enzyme. G6PDH is the ﬁrst
enzyme of the pentose phosphate pathway and is essential
for the defense of the parasite against oxidative stress. T.
brucei and T. cruzi G6PDHs are inhibited by steroids such as
dehydroepiandrosteroneandderivativesinanuncompetitive
way. The Trypanosoma enzymes are more susceptible to inhi-
bition by these compounds than the human G6PDH. These
compounds are presently considered as promising leads for
the development of new parasite-selective chemotherapeutic
agents.
In the seventh paper, A. F. Coley et al. have discussed the
possibility of therapeutic development targeting glycolysis
in African trypanosomes. The parasite is limited to using
glycolysis of host sugar for ATP production while infecting
the human host. This dependence on glucose breakdown
presents a series of targets for potential therapeutic develop-
ment, many of which have been explored and validated as
therapeutic targets experimentally and has been addressed in
this paper in detail.
In the eighth paper, S. L. de Castro et al. have given
a good overview of experimental chemotherapy in the
Chagas disease which is caused by Trypanosoma cruzi, and
it aﬀects approximately eight million individuals in Latin
America. The authors have presented a nice biochemical and
proteomic overview of potential T. cruzi targets with refer-
ence to amidine derivatives and naphthoquinones that have
showed the most promising eﬃcacy against T. cruzi.
In the ninth paper, A. K. Haldar et al. have classically
demonstrated the current status and future directions for
the use of antimony in the treatment of leishmaniasis. The
standard treatment of Kala-azar in the recent past has been
the use of pentavalent antimonials (SbV) but there has been
progressive rise in treatment failure to Sb(V) due to the
problem of chemoresistance that has limited its use in the
treatment program in the Indian subcontinent. However,
it has been shown recently that some of the peroxovana-
dium compounds have Sb(V) resistance modifying ability
in experimental infection with Sb(V) resistant Leishmania
donovani isolates in murine model. Thus vanadium com-
pounds may be used in combination with Sb(V) in the
treatment of Sb(V) resistance cases of kala-azar.
In the tenth paper, R. Duncan et al. have presented a
comprehensive overview of the genes involved in Leishma-
nia pathogenesis with reference to the potential for drug
target selection. Proteins that are diﬀerentially expressed
or required in the amastigote life cycle stage found in the
patientarelikelytobeeﬀectivedrugtargets.Severalexamples
and their potential for chemotherapeutic disruption have
been presented in this paper. The programmed cell death
pathway that is now recognized among protozoan parasites
is reviewed for some of its components and evidence that
suggests that they could be targeted for anti-parasitic drug
therapy has been presented.
In the next paper, A. Biswas et al. have discussed the
role of cAMP signaling in the survival and infectivity of the
protozoan parasite Leishmania donovani. While invading
macrophages, L. donovani encounters striking shift in tem-
perature and pH that act as the key environmental trigger for
diﬀerentiation and increase cAMP level and cAMP-mediated
responses. A diﬀerentially expressed soluble cytosolic cAMP
phosphodiesterase (LdPDEA) might be related to infection
establishment by shifting trypanothione pool utilization
bias toward antioxidant defense. This paper explains the
signiﬁcance of cAMP signaling in parasite survival and
infectivity.
In the twelfth paper, Md. Shadab and N. Ali have ele-
gantly discussed the evasion of host defense mechanism by
L. donovani. They have presented a detailed account of the
subversion and signaling pathways that allow the parasites to
get rid of the host defense mechanism.
In the last paper, A. Ghoshal and C. Mandal have
presented a detailed perspective of sialic acids that serve
as important determinants inﬂuencing the parasite biology.
Despite the steady progress in the ﬁeld of parasite glycobiol-
ogy, sialobiology hasbeen alesstraverseddomain ofresearch
in leishmaniasis. This paper focuses on identiﬁcation, char-
acterization, and diﬀerential distribution of sialoglycotope
having the linkage-speciﬁc 9-O-acetylated sialic acid inMolecular Biology International 3
promastigotes of diﬀerent Leishmania sp. causing diﬀerent
clinical ramiﬁcations.
There are other areas of relevance not covered in the
volume, that is, prophylactic and therapeutic vaccination,
targeted drug delivery, and antigenic variation. However, the
present issue covers a signiﬁcant area of the subject and will
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